← Back to Screener
Telomir Pharmaceuticals, Inc. Common Stock (TELO)
Price$1.48
Favorite Metrics
Price vs S&P 500 (26W)-20.87%
Price vs S&P 500 (4W)0.36%
Market Capitalization$49.85M
All Metrics
Book Value / Share (Quarterly)$0.17
Indicated Dividend (Annual)$0.00
Cash Flow / Share (Quarterly)$-0.11
Price vs S&P 500 (YTD)4.88%
EPS (TTM)$-0.34
10-Day Avg Trading Volume0.09M
EPS Excl Extra (TTM)$-0.34
EPS (Annual)$-0.33
ROI (Annual)-176.10%
Cash / Share (Quarterly)$0.21
ROA (Last FY)-141.84%
EBITD / Share (TTM)$-0.34
Cash Flow / Share (Annual)$-0.11
P/B Ratio8.43x
P/B Ratio (Quarterly)7.73x
Net Interest Coverage (TTM)-2.85x
ROA (TTM)-259.29%
EPS Incl Extra (Annual)$-0.33
Current Ratio (Annual)5.14x
Quick Ratio (Quarterly)5.10x
3-Month Avg Trading Volume0.14M
52-Week Price Return-41.77%
52-Week High$3.10
EPS Excl Extra (Annual)$-0.33
26-Week Price Return-12.12%
Quick Ratio (Annual)5.10x
13-Week Price Return7.41%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)5.14x
Enterprise Value$42.566
Cash / Share (Annual)$0.21
3-Month Return Std Dev67.44%
ROE (Last FY)-176.10%
Net Interest Coverage (Annual)-1.45x
EPS Basic Excl Extra (Annual)$-0.33
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-0.34
ROI (TTM)-184.69%
Revenue / Share (Annual)$0.00
Price vs S&P 500 (52W)-76.86%
Year-to-Date Return9.02%
5-Day Price Return11.54%
EPS Normalized (Annual)$-0.33
Month-to-Date Return11.54%
EBITD / Share (Annual)$-0.33
EPS Basic Excl Extra (TTM)$-0.34
P/B Ratio (Annual)7.73x
Book Value / Share (Annual)$0.17
Price vs S&P 500 (13W)4.54%
Beta0.99x
Revenue / Share (TTM)$0.00
ROE (TTM)-184.69%
52-Week Low$1.05
Industry Peers — Pharmaceuticals(309)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
TELOTelomir Pharmaceuticals, Inc. Common Stock | — | — | — | — | $1.48 |
LLYEli Lilly & Co. | 13.45x | 44.70% | 83.04% | 27.59% | $919.90 |
JNJJohnson & Johnson | 5.82x | 7.87% | 67.95% | 14.90% | $230.69 |
ABBVABBVIE INC. | 5.97x | 8.57% | 71.62% | -2.88% | $203.71 |
MRKMerck & Co., Inc. | 4.51x | 1.31% | 78.55% | 21.23% | $117.10 |
AZNAstraZeneca PLC | 5.39x | 8.63% | 81.31% | 21.88% | $200.69 |
NVSNovartis AG | 4.87x | 8.91% | 75.82% | 15.26% | $150.99 |
NVONovo-Nordisk A/S | 3.74x | 6.43% | 80.98% | 20.66% | $40.46 |
ABTAbbott Laboratories | 3.71x | 6.59% | 56.50% | 8.20% | $96.00 |
PFEPfizer Inc. | 2.50x | -1.64% | 75.81% | -3.51% | $27.52 |
BMYBristol-Myers Squibb Co. | 2.52x | -0.22% | 72.63% | — | $59.13 |
About
Telomir Pharmaceuticals is a preclinical-stage biopharmaceutical company developing Telomir-1, a small molecule designed to lengthen and protect telomeres, the protective DNA caps of chromosomes that shorten with age. The company aims to address age-related diseases—including Progeria, diabetes, cancer, Alzheimer's disease, and osteoarthritis—by targeting the underlying cellular mechanisms of aging rather than treating individual symptoms.